explore -WSS

explore

author：Wikipedia 2025-08-26 10:52:45 - browse：7214

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： The a glaring gap in research on serious mental illness and primary care

focus

knowledge

WSS

Cue Health's Covid

Element Biosciences CEO lays out genome sequencing strategy

MassMutual is introducing free genetic testing for members

H5N1 bird flu found in pasteurized milk: what we know

The cancer stories no one wants to hear

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Wikipedia

explore

Wikipedia

How one medical school became remarkably diverse

FTC falls short on scrutinizing hospital mergers, study says

Medical leaders decry Supreme Court decision on affirmative action

A controversial new treatment promises to make little people taller

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

When waiting feels immoral: Empathy in the emergency department

Walensky prepares to leave CDC — and Congress — behind

FDA scientists endorse Pfizer/BioNTech Covid

ChatGPT in medicine: STAT answers readers' burning questions

Cue Health's Covid

leisure time

Getting Alzheimer's drug Leqembi to patients can be a challenge

Why does health care cost so much? A reading guide

Close Medicare's dangerous gaps in addiction treatment coverage

Chris Christie meets with Zelenskyy during Ukraine trip

Late stage cancers on the rise after pandemic delayed screenings

Alnylam reports growth in sales of rare disease treatments

focus

knowledge

focus

focus